Navigation Links
Kendle Advances Early Stage Drug Development with ElMindA's Innovative Brain Network Activation Technology
Date:6/15/2010

External Link';s.eVar3=s.prop5;s.prop15='96365609';s.tl(this,'o','ExternalLink');" target='_blank' href="http://www.elminda.com/">www.elminda.com.

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the world's largest global providers of Phase I-IV services, we offer experience spanning more than 100 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges.

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 500, Cincinnati, OH 45202 or from the Company's Web site at www.kendle.com.

Forward-Looking Statements

Certain statements and information contained in this press release may be deemed to be forward-looking statements under federal securities laws and the provisions of the Private Securities Litigation Reform Act of 1995 and Kendle intends that such forward-looking statements be subject to the safe-harbor created thereby. All such forward-looking statements, including those regarding the benefits of Kendle's use of
'/>"/>

SOURCE Kendle International Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Kendle Director of Global Safety and Pharmacovigilance, Drew Kilpatrick, PhD, Named One of Ten Notable People in R&D
2. Kendle Executive to Share Insights at World Pharma Trials Asia 2010
3. Kendle is First Global CRO to Achieve ISO 9001:2008 Certification in China Through Beijing Affiliate
4. Kendle Launches New Global Biostatistics Infrastructure
5. Kendle Receives Approval From Indian Government to Proceed With Development of Operations Center in Special Economic Zone
6. Kendle Appoints J. Michael Sprafka, MPH, PhD, Vice President, Kendle Consulting
7. Kendle Announces Details Regarding Third Quarter 2009 Earnings Conference Call and Webcast
8. Kendle Experts to Share Insights at the Regulatory Affairs Professionals Society Annual Conference and Exhibition
9. Kendle Experts to Present at the Drug Information Association 44th Annual Meeting
10. Simulated Surgical Systems, LLC Partners to Bring Simulation Advances to Surgical Training
11. Gamma Knife Users Share Latest Advances for Treating Cancer, Other Brain Disorders at Society Meeting in Greece
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... -- The new 13-valent pneumococcal conjugate vaccine (PCV13) appears ... prior to 2010, the 7-valent pneumococcal conjugate vaccine (PCV7), ... Vaccine. The U.S. Food and Drug Administration ... series of trials. These trials found that PCV13, which ... the previously used PCV7, did not increase the risk ...
(Date:5/22/2013)... , 22. Mai 2013 Kepner-Tregoe ... Beratung, gab heute bekannt, dass der Veteran ... , zum Hauptgeschäftsführer ernannt wurde. Geraghty,s ... Industriebereich wo er zahlreiche Führungspositionen bei Fertigungsunternehmen ... Baxter an, der als Kepner-Tregoe Hauptgeschäftsführer gedient ...
(Date:5/22/2013)... May 22, 2013  MGT Capital Investments, Inc. (NYSE ... at the Second Annual Marcum LLP MicroCap Conference on ... City at the Grand Hyatt Hotel.  ... Officer, will update investors and answer questions. ... presentation is scheduled to begin at 9:30 a.m. EDT.  ...
Breaking Medicine Technology:Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 2Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 3Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 4Kepner-Tregoe, Inc. befördert Chris Geraghty zum Hauptgeschäftsführer 2Kepner-Tregoe, Inc. befördert Chris Geraghty zum Hauptgeschäftsführer 3MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 2MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 3MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 4
... The bio-pharmaceutical marketplace - and the Oncology therapeutic ... new medicines and technologies create valuable market opportunities. ... organizations with new Oncology products are scrutinizing their ... Commercial executives in the Oncology therapeutic area make ...
... 28 bioMerieux - a world leader in the ... announced the U.S. launch of chromID MRSA, a simple ... product recently received FDA 510(k) clearance for the detection ... high-morbidity healthcare-associated infections (HAI) in U.S. hospitals.(1) The current ...
Cached Medicine Technology:Educating the Marketplace to Support Successful Oncology Product Launches 2bioMerieux Adds Methicillin-resistant Staphylococcus aureus (MRSA) Screening Tool to its Arsenal 2bioMerieux Adds Methicillin-resistant Staphylococcus aureus (MRSA) Screening Tool to its Arsenal 3bioMerieux Adds Methicillin-resistant Staphylococcus aureus (MRSA) Screening Tool to its Arsenal 4
(Date:5/22/2013)... 2013 Spinal Elements, an innovative ... in Carlsbad to 3115 Melrose Drive, Suite 200, ... company’s continued and projected growth and has expanded ... feet to over 40,000 square feet. , ... indicated, “Our investment in these state-of-the-art facilities will ...
(Date:5/22/2013)... Lawrenceville, NJ and Los Angeles, CA (PRWEB) May 22, ... chairman of the board, The J. M. Smucker Company, ... GS1 Lifetime Achievement Awards yesterday at the GS1 General ... Los Angeles, California. Mr. Smucker and Mr. Wegman were ... adoption of GS1 Standards - the most broadly used ...
(Date:5/22/2013)... -- Children who are physically, sexually or emotionally abused ... in life, a new review suggests. British researchers ... to be obese as adults. They concluded that child ... for obesity. "We found that being maltreated as ... adult life," study author Dr. Andrea Danese, a child ...
(Date:5/22/2013)... p53 turns off cancer. However, when existing drugs boost p53, only ... study published in the journal Cell Reports shows how: ... more of the protein p21 than the protein PUMA; tumors that ... the current study shows a handful of genes that control this ... mutated cancer genes. Tumors turn it off and then they can ...
(Date:5/22/2013)... May 22, 2013 The new 13-valent pneumococcal conjugate ... previous version used prior to 2010, the 7-valent pneumococcal ... published today in Vaccine . , The U.S. ... in 2010 after a series of trials. These trials ... of pneumococcal types than the previously used PCV7, did ...
Breaking Medicine News(10 mins):Health News:Spinal Elements®, Inc. Relocates Corporate Headquarters in Carlsbad 2Health News:Tim Smucker and Danny Wegman Honored With GS1 Lifetime Achievement Awards 2Health News:Tim Smucker and Danny Wegman Honored With GS1 Lifetime Achievement Awards 3Health News:Abused Children at Risk for Obesity as Adults: Study 2Health News:Study details genes that control whether tumors adapt or die when faced with p53 activating drugs 2Health News:Study finds new pneumococcal vaccine appears to be as safe as previously used vaccine 2
... Inc. (Amex:,ULU) announced today that Ronald A. Ahrens has ... Mr. Ahrens has been an advisor to Merck ... of Merck Consumer Healthcare Group Worldwide.,He had previously served ... From 1985 to 1990 Mr. Ahrens was Consumer,Group President, ...
... 23 The American Society of,Transplantation (AST) recently ... Award, to Richard N. Fine, M.D. at the,American ... a,senior investigator whose lifelong work has advanced the ... the field and the,AST have been broad and ...
... clot-busting tPA, researchers say , , MONDAY, June 23 (HealthDay ... boost stroke patients, survival, new research suggests. , Gleevec, ... as chronic myelogenous leukemia (CML), will be tested to ... the side effects of the clot-dissolving drug tissue plasminogen ...
... and Public Health Experts to Raise Public ... Awareness Via Mobile Media, ... HIV testing is getting out to the general public, thanks to,the ... most reliable wireless voice and data network,announced today its continued effort ...
... 23 Boston Scientific,Corporation (NYSE: BSX ) today ... will help service veterans and the active armed forces,better ... has recently,passed the Veterans Mental Health Improvements Act, which ... originally introduced,by Senator Daniel Akaka (D-HI). The bill calls ...
... Therapeutic Vaccines for Infectious ... Diseases, ... on emerging understanding of the human immune system,today announced the closing of ... Partners, The Column Group and Versant,Ventures. The Column Group initially incubated the ...
Cached Medicine News:Health News:ULURU Inc. Announces the Appointment of Ronald A. Ahrens to the Board of Directors 2Health News:AST Awards Richard N. Fine, M.D. 2008 Ernest Hodge Distinguished Achievement Award 2Health News:Cancer Drug Gleevec Could Fight Stroke 2Health News:Cancer Drug Gleevec Could Fight Stroke 3Health News:Verizon Wireless Continues Support of National HIV Testing Awareness Campaign 2Health News:Verizon Wireless Continues Support of National HIV Testing Awareness Campaign 3Health News:Boston Scientific Welcomes Progress on Pain Care Legislation 2Health News:Boston Scientific Welcomes Progress on Pain Care Legislation 3Health News:Boston Scientific Welcomes Progress on Pain Care Legislation 4Health News:Immune Design Announces $18 Million Series A Financing 2Health News:Immune Design Announces $18 Million Series A Financing 3
... Oximeter with SAC (Serial Autocorrelation) Technology uses ... extract SpO 2 , pulse strength, and ... This cost-effective compact monitor incorporates clinical, ... features, and a data log or trend ...
... Autocorr Plus, the fourth in the ... pulse oximeter/ECG/Respiration Monitor, with 3 or ... oximetry with SAC (Serial Autocorrelation) technology, ... screen display provides two user configurable ...
... The BCI 3180 Pulse Oximeter is a ... SpO 2 pulse rate and pulse ... adult. This AC or battery powered ... low alarm limits and up to 30 ...
... ReZoom intraocular lens is a second-generation refractive ... with greater independence from glasses than monofocal ... a range of vision that monfocals cannot ... technology distributes light over five optic zones ...
Medicine Products: